Condition

Primary Mediastinal Large B-cell Lymphoma (PMBCL) clinical trials and research

• 13Clinical trials
• 6Countries

Newest Primary Mediastinal Large B-cell Lymphoma (PMBCL) clinical trials

All recruiting trials (13)

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• TC011 (CD19 CAR-T) for relapsed or refractory large B‑cell lymphoma

  This will test a CD19-targeted CAR-T therapy called TC011 in adults whose large B‑cell lymphoma has relapsed or not responded after prior treatments.

  Recruiting Phase 1/2 TICAROS Co., Ltd. · Seoul, Seoul · NCT07473167

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Treatment of relapsed large B-cell lymphoma with WZTL-002 CAR T-cells

  This study is testing a new CAR T-cell therapy called WZTL-002 to see if it can help adults with relapsed large B-cell lymphoma that hasn't worked with standard chemotherapy.

  Recruiting at 3 sites Phase 2 Malaghan Institute of Medical Research · Auckland, Auckland and 2 other locations · NCT06486051

• Observational study on CAR-T therapy for lymphoma in Italy

  This study looks at how well CAR-T therapy works and its side effects for people with lymphoma in Italy by tracking their health over three years.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT06339255

• CLIC-2201 treatment for relapsed B cell cancers

  This study is testing a new CAR-T cell therapy called CLIC-2201 to see if it can help people with relapsed B cell cancers feel better and improve their treatment outcomes.

  Recruiting at 7 sites Phase 1 British Columbia Cancer Agency · Calgary, Alberta and 6 other locations · NCT06208735

• Using CD79b-19 CAR T cells to treat Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06026319

• Combining pembrolizumab with CAR T-cell therapy for recurrent primary mediastinal large B-cell lymphoma

  This study is testing if adding pembrolizumab to CAR T-cell therapy can help people with recurrent primary mediastinal large B-cell lymphoma feel better and live longer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT05934448

• Healthy Lifestyle Plan for Lymphoma Survivors

  This study is testing whether a special health plan that includes lifestyle changes and nutrition advice can help lymphoma survivors feel better after they've been in remission for a while.

  Recruiting at 34 sites Fondazione Italiana Linfomi - ETS · Ancona, Ancona and 39 other locations · NCT05934084

• Evaluation of CAR-T cell therapy in certain blood cancers

  This study is testing how well CAR-T cell therapy works and lasts in patients with certain types of blood cancers, while also looking for signs that could predict how they respond to treatment and any side effects they might have.

  Recruiting Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Brescia · NCT05366569

• Efficacy and safety of CRC01 for adult patients with large B-cell lymphoma

  This study is testing a new CAR-T therapy called CRC01, combined with other medications, to see if it can help adults with hard-to-treat large B-cell lymphoma feel better.

  Recruiting at 2 sites Phase 1/2 Curocell Inc. · Seoul and 1 other locations · NCT04836507

• CAR-T cell therapy for patients with relapsed B cell cancers

  This study is testing a new CAR-T cell therapy for adults with relapsed B cell cancers to see how well it works and if different manufacturing methods make a difference in treatment outcomes.

  Recruiting Phase 1/2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04186520

Related topics

Quick answers

How many Primary Mediastinal Large B-cell Lymphoma (PMBCL) clinical trials are recruiting right now?

13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 6 countries. The most sites are in United States (5 trials), Italy (3 trials), South Korea (2 trials), Canada (1 trial), New Zealand (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 5, Phase 1: 3, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →